BAT Marks WVD22

Posted 31st May 2022 by Dave Cross
To mark World Vape Day, yesterday, Monday 30 May, British American Tobacco published an ‘at a glance’ Science and Innovation e-zine. The publication is intended to provide a simple introduction to Research and Development at the tobacco company and provides an insight into the level of commitment to shift from traditional products.

The e-zine describes the new science underpinning BAT’s reduced-risk tobacco and nicotine products, such as vapour and modern oral. It explains BAT’s corporate purpose of A Better Tomorrow, and how the company is advancing Tobacco Harm Reduction by developing innovative new products*, backed by “robust science”.

Dr David O’Reilly, the Director of Scientific Research said: “We recognise the harm causedby tobacco and we are on a journey to rapidly transform ourselves by reducing the health impact of the business and, ultimately, build A Better    Tomorrow.”

British American Tobacco says that since 2018 it has invested over £1.2 billion to develop its New Category products.

Dr Sharon Goodall, BAT’s Group Head of Regulatory Science, said: “Vaping is playing an increasingly important role in Tobacco Harm Reduction, with 2.7 million users in England alone**. World Vape Day is an important moment to recognise this progress and encourage those who would otherwise continue to smoke to choose an alternative tobacco or nicotine product. For smokers to make an informed choice, it is critical that they understand how alternative tobacco and nicotine products are reduced risk compared to continuing to smoke***.

“BAT has been generating scientific evidence for many years to assess how our vapour products compare to cigarettes, including data to show they have 99% less toxicants compared to cigarettes*†. This is important information that, along with other scientific evidence, supports the conclusion that vapour products are less risky alternatives to cigarettes.”


*Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk-free and are addictive.

**This is according to the February 2021 independent report on vaping products commissioned by Public Health England.

***Products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to Food and Drug Administration (FDA) regulation and no reduced-risk claims will be made as to these products without FDA clearance.

†This is a comparison between smoke from a 1R6F reference cigarette (approx. 9mg tar) and vapour from the Vuse ePod and ePen3 in terms of the 9 harmful components the World Health Organization recommends to reduce in cigarette smoke.

 Dave Cross
Article by Dave Cross
Freelance writer, physicist, karateka, motorbikes, and dog walker
JSB Vape